Dementia and Alzheimer's disease may be more common in women with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), an association likely driven by metabolic comorbidities. (Journal of the Endocrine Society) The investigational enzyme replacement therapy efzimfotase alfa failed to hit its primary endpoint of improvement in the 6-Minute Walk Test in a phase III trial of treatment... Dementia and Alzheimer's disease may be more common in women with polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), an association likely driven by metabolic comorbidities. (Journal of the Endocrine Society) The investigational enzyme replacement therapy efzimfotase alfa failed to hit its primary endpoint of improvement in the 6-Minute Walk Test in a phase III trial of treatment-naive patients with hypophosphatasia, according to maker AstraZeneca. A low-fat plant-based diet was associated with improved liver fat content, insulin sensitivity, and beta-cell function in adults with type 2 diabetes in a single-arm trial. (BMJ Open Diabetes Research & Care) From 2017 to 2023, presentation rates for nonbinary youth increased 2.7-fold compared with binary transgender youth at an Australian pediatric gender clinic. Zealand Pharma said its investigational amylin analog petrelintide led to an average weight reduction of up to 9.2% at 28 weeks and with low discontinuation rates, compared with a 2% weight reduction with placebo, in a phase II trial of adults with overweight/obesity and type 2 diabetes. News and commentary from the endocrinology world

Original title: “Bootleg Retatrutide Deaths? PMOS and Dementia; Weight-Loss Drug to Be Discontinued | MedPage Today”